drugset / Trial / NCT04785300
ALSENLITE: Senolytics for Alzheimer's Disease
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to evaluate the safety and feasibility of using Dasatinib and Quercetin together in subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease.
Timeline
- Start
- 2022-07-06
- Primary completion
- 2026-12
- Completion
- 2026-12
Publications
- Andrews TD, Day GS, Irani SR, Kanekiyo T, Hickson LJ. Uremic Toxins, CKD, and Cognitive Dysfunction. J Am Soc Nephrol. 2025 Jun 1;36(6):1208-1226. doi: 10.1681/ASN.0000000675. Epub 2025 Feb 26.
- Guerrero A, De Strooper B, Arancibia-Carcamo IL. Cellular senescence at the crossroads of inflammation and Alzheimer's disease. Trends Neurosci. 2021 Sep;44(9):714-727. doi: 10.1016/j.tins.2021.06.007. Epub 2021 Aug 5.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quercetin | Small molecule | 1000 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |